{"columns":["outcome_id","target_population","exposure","comparators","eligible_designs","time_zero_and_latency","estimand","minimum_confounders","effect_measures_pooled_separately"],"rows":[["O28","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control","Time zero at initiation; risk window from day 1","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; BMI or obesity; diabetes duration or HbA1c; prior gallbladder disease; calendar time","HR; OR (case control); RR"],["O29","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control","Time zero at initiation; risk window from day 1","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; alcohol use; gallstone disease; hypertriglyceridemia; prior pancreatitis; calendar time","HR; OR (case control); RR"],["O32A","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control; registry based case control","Time zero at initiation; latency 1 year (cases in the first year excluded); sensitivity analysis without latency","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; BMI; thyroid disease history; radiation exposure where available; thyroid imaging intensity","HR; OR (case control)"],["O32B","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control; registry based case control","Time zero at initiation; latency 1 year (cases in the first year excluded); sensitivity analysis without latency","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; BMI; thyroid disease history; radiation exposure where available; thyroid imaging intensity","HR; OR (case control)"],["O33","Adults with type 2 diabetes initiating treatment","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control","Time zero at initiation; risk window from day 1; early HbA1c reduction treated as a mediator not a confounder","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; diabetes duration; HbA1c; baseline retinopathy; insulin use","HR; OR (case control)"],["O34","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control; self controlled case series","Time zero at initiation; risk window during exposure","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; diabetes; hypertension; obstructive sleep apnea; cup to disc ratio where available","HR; OR (case control); incidence rate ratio (self controlled); each pooled separately"],["O35A","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control","Time zero at initiation; risk window from day 1","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; prior psychiatric disorder; prior self harm; antidepressant use; substance use","HR; OR (case control)"],["O35B","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control","Time zero at initiation; risk window from day 1","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; prior psychiatric disorder; prior self harm; antidepressant use; substance use","HR; OR (case control)"],["O36A","Adults undergoing endoscopy or procedures with anesthesia or sedation","Current use of a GLP-1 receptor agonist containing drug at the procedure","Non use at the procedure; current use of an active comparator in a separate stratum","Cohort of procedures; case control","Time zero at the procedure","Risk per procedure","Age; sex; diabetes; gastroparesis; procedure type; sedation type; fasting duration","OR; RR (risk per procedure)"],["O36B","Adults undergoing endoscopy or procedures with anesthesia or sedation","Current use of a GLP-1 receptor agonist containing drug at the procedure","Non use at the procedure; current use of an active comparator in a separate stratum","Cohort of procedures; case control","Time zero at the procedure","Risk per procedure","Age; sex; diabetes; gastroparesis; procedure type; sedation type; fasting duration","OR; RR (risk per procedure)"],["O37A","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation","Time zero at initiation; risk window from day 1","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; diabetes; prior gastrointestinal surgery; opioid use","HR"],["O37B","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation","Time zero at initiation; risk window from day 1","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; diabetes; prior gastrointestinal surgery; opioid use","HR"],["O38","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control","Time zero at initiation; latency 1 year; sensitivity analysis without latency","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; BMI; smoking; alcohol; diabetes duration; chronic pancreatitis","HR; OR (case control)"],["O39","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation; nested case control","Time zero at initiation; latency 1 year; sensitivity analysis without latency","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; BMI; smoking; alcohol; diabetes duration; prior cancer screening","HR; OR (case control)"],["O120","Pregnancies of people with type 2 diabetes or obesity","Exposure in the periconception period or first trimester","Unexposed pregnancies with the same indication; pregnancies exposed to other glucose lowering drugs in a separate stratum","Cohort","Time zero at conception","Risk per pregnancy","Maternal age; BMI; diabetes and HbA1c; other teratogenic medicines","RR; OR"],["O121","Adults initiating treatment for type 2 diabetes or obesity","Initiation of a GLP-1 receptor agonist containing drug","Initiation of an active comparator (SGLT2 inhibitor or DPP-4 inhibitor preferred; other glucose or weight lowering drug); non users only in a separate secondary stratum","New user cohort; active comparator new user cohort; target trial emulation","Time zero at initiation; risk window from day 1","Analyzed in separate syntheses: (a) initial treatment (intention to treat analogue) and (b) on treatment; never combined","Age; sex; baseline eGFR; diuretic and renin angiotensin system inhibitor use; heart failure","HR"]]}